Sabitlenmiş Tweet
KMittaloncMD
598 posts
KMittaloncMD
@KMittalmd
GU Medical Oncologist. Clinical investigator. Cleveland Clinic alum. Views my own.
Katılım Şubat 2021
304 Takip Edilen517 Takipçiler
KMittaloncMD retweetledi
ICYMI: Watch this new video on the EA8231 #ClinicalTrial for patients with advanced #UrothelialCancer. @MonikaJoshimd & @PGrivasMDPhD discuss the rationale, eligibility, & potential impact. View here: bit.ly/ea8231-video #BladderCancer
English
Looking forward to co-hosting our quarterly webinar for @ASPIRE_CoP - an @asco community of practice, with my co-host @afreenshariffmd featuring speakers @VKazakovaMD and Noha Abdel-Wahab
Cc:@UMass_Medicine @dukeendocrinol1 @ClevelandClinic @huntsmancancer
ASPIRE Community of Practice@ASPIRE_CoP
Join us for our upcoming webinar! 📅 March 27, 2026 | 3 PM CST @ASPIRE_CoP Supported by our community: @FunchainMD, @KMittalMD, @afreenshariffmd, @BryanSchne90417, @EladSharonMD, @mhadfield30, @lexmeara Scan the QR code below or join via the link in the replies. 👇
English
KMittaloncMD retweetledi
Join us for our upcoming webinar!
📅 March 27, 2026 | 3 PM CST
@ASPIRE_CoP
Supported by our community: @FunchainMD, @KMittalMD, @afreenshariffmd, @BryanSchne90417, @EladSharonMD, @mhadfield30, @lexmeara
Scan the QR code below or join via the link in the replies. 👇
English
KMittaloncMD retweetledi
@GUconference It’s an honor to be in this era with super stars @shilpaonc @EHeath4100 @apolo_andrea @ERPlimackMD @HymaPolimera @KMittalmd and all our colleagues who support us.
English
KMittaloncMD retweetledi
📚 Reading Corner: GI #irAE Insights
Two critical gaps in managing GI immune-related Adverse Events:
1️⃣ Risk factors and clinical course of IBD in patients receiving cancer therapy
2️⃣ IMDC with normal biochemical, endoscopic, and histologic findings.
Study links below. 👇
English
KMittaloncMD retweetledi
I’m looking forward to joining @BradMcG04 & colleagues at the 2026 @ASCO Direct GU Conference, taking place March 14–15 in Boston, where we’ll discuss key updates and clinical implications across prostate, bladder, and kidney cancers @BradMcG04
📺 Learn more and register for the officially licensed ASCO Direct GU. Registration is complimentary as always: totalhealthoncology.com/upcoming-oncol…
Amazing faculty -
@Dr_RaviMadan
Atish Chowdhury Dana-Farber
Michael Serzan Harvard Univ
Sophia Kamran Massachusetts Gen
Karie Runcie Columbia University
Neil Shah MSKCC
Dave Gau Univ Pittsburgh
Xiao Wei Dana-Farber
Kriti Mittal UMass
English
KMittaloncMD retweetledi
Hope that many centers can open this important P3 trial asking IO-rechallenge question in advanced urothelial Ca! Huge effort @MonikaJoshimd @eaonc et al.
@MattGalsky @MattMilowsky @sonpavde @arkhaki @AbhiTrip87 @rohitjainMD @JasonBrownMDPhD @RandySweis @OncoBellmunt @KMittalmd
ECOG-ACRIN Cancer Research Group@eaonc
#ClinicalTrial EA8231, led by @MonikaJoshimd & @PGrivasMDPhD, is a phase 3 randomized study exploring a new treatment approach for patients with treatment-refractory, locally-advanced or metastatic #UrothelialCancer. More information here: bit.ly/ea8231-study
English
KMittaloncMD retweetledi
At #GU26 : ⬆️ KIM1 isn’t specific to clear cell RCC and is ⬆️ in metastatic papillary RCC too - it makes sense as it was originally a marker of kidney injury rather than specifically clear cell cancer cells. But there are problems too - have a listen @scocmem @BartsECMC @DrChoueiri @montypal @brian_rini
Uromigos@Uromigos
@scocmem presents her work on KIM-1 in papillary RCC for our @Uromigos Unsung Hero Award for RCC #ASCOGU 2026
English
KMittaloncMD retweetledi
The K-COMPASS study by @ChadTangMD shows how ctDNA and KIM-1 are prognostic and can be used to estimate treatment-free survival in patients with oligometastatic RCC #ASCOGU26 @PavlosMsaouel
English
Thank you @KidneyCancer for the fantastic opportunities the Women in RCC program provides for GU oncologists @DrVaishampayan @TiansterZhang
Excellent session on The Art of Adaption this morning.
English
KMittaloncMD retweetledi
amazing to work with @JCensits @eaonc in this important phase 2-3 neoadjuvant UTUC trial!Thanks Noah Hahn & all co investigators for your support!Let’s keep accruing to cisplatin-fit cohorts @spsutkaMD @AbhiTrip87 @SuzanneColeMD @RubenRaychaud
@Uromigos @KMittalmd @MonikaJoshimd
MJ@MonikaJoshimd
Congratulations to @JCensits and @eaonc team for sharing part of EA8192 results for the arm C. Imp study that could give insight into next SOC for Upper tract NAC Rx ddMVAC and durva. @PGrivasMDPhD pls enroll on the study
English
KMittaloncMD retweetledi
Congratulations to @JCensits and @eaonc team for sharing part of EA8192 results for the arm C. Imp study that could give insight into next SOC for Upper tract NAC Rx ddMVAC and durva. @PGrivasMDPhD pls enroll on the study
English
KMittaloncMD retweetledi
PCWG4 is published! #GU26 Thanks to @ThePCCTC and my co chairs Howard Scher and Mike Morrison and the 65 co-authors of these new trial guidelines! @DukeCancer @JCO_ASCO ascopubs.org/doi/10.1200/JC…
English
Love this “Every trial has a promise” @DrYukselUrun @PGrivasMDPhD. Look forward to learning the latest in GU Onc science @asco #GU26
Petros Grivas@PGrivasMDPhD
Well said @DrYukselUrun we work daily with patients/families in mind! Science is the “bridge” to better outcomes!Looking forward to #GU26 @ASCO @ASCOPres @jrgralow @CliffordHudis @EMittendorfMD @fredhutch @HutchPresident @OncoAlert Kudos to @apolo_andrea &team for stellar agenda
English
KMittaloncMD retweetledi
Thanks @neerajaiims highlighting our phase 2 trial poster with @JCensits et al.
@eaonc #GU26 @fredhutch @OncoAlert @apolo_andrea @sonpavde @spsutkaMD @HsiehLab @ZakhariaYousef @AbhiTrip87 @FaltasLab @KMittalmd @RubenRaychaud @Uromigos @urotoday @IBCG_BladderCA @BladderConnect
Neeraj Agarwal, MD, FASCO@neerajaiims
Ab#749 @ASCO #GU26 by @JCensits @PGrivasMDPhD @eaonc👉bit.ly/474KOKc👉Neoad Gem-Durva in cisplatin-unfit pts w/ high grade UTUC #bladdercancer👉pCR 10%, <ypT2N0/X 33%, promising 1-year EFS rate, manageable tox👉Ph3 ongoing in cisplatin-fit pts👇@OncoAlert @urotoday
English
KMittaloncMD retweetledi
Ab#749 @ASCO #GU26 by @JCensits @PGrivasMDPhD @eaonc👉bit.ly/474KOKc👉Neoad Gem-Durva in cisplatin-unfit pts w/ high grade UTUC #bladdercancer👉pCR 10%, <ypT2N0/X 33%, promising 1-year EFS rate, manageable tox👉Ph3 ongoing in cisplatin-fit pts👇@OncoAlert @urotoday
English
KMittaloncMD retweetledi
We are thrilled to welcome our 2026 @ASCO @ASPIRE CoP Champions @KmittalMD (@UMassChan) and @AfreenshariffMD (@DukeHealth). Together, they bring a powerful vision: strengthening connections among oncology + non-oncology clinicians to improve #irAE care
English
KMittaloncMD retweetledi
Don’t forget to join us for the ASPIRE Quarterly case discussion tonight at 5:30 pm CST: link 👇
ASPIRE Community of Practice@ASPIRE_CoP
🗓️ ASPIRE Quarterly Case Discussion Announcement 🖥️Feb 17, 2026 @ 5:30 PM CST. System-focused discussion on Liver Toxicity (Dr. Hao Chi Zhang) + Rheum Toxicity (Dr. Alexa Meara) Register for the Zoom webinar here: mdacc.zoom.us/j/92105246733?… CME code: 41872
English
KMittaloncMD retweetledi
@PGrivasMDPhD @eaonc @fredhutch @ZakhariaYousef @HsiehLab @rohitjainMD @DrScottTagawa Encouraging to see this. Hope folks open Ea8231 in their sites. Not much competition in this refractory space. We have done our best to exclude CPI primary refractory. Study is easier to do at your center @BigTenCRC @shilpaonc @DrChoueiri @eaonc
English